A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients

Introduction Eculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat generalized myasthenia gravis (gMG) patients. The objective of this study is to describe the clinical response to both treatments in a real-life settin...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of neurology Vol. 271; no. 9; pp. 6209 - 6219
Main Authors:	Pane, Chiara, Di Stefano, Vincenzo, Cuomo, Nunzia, Sarnataro, Alessio, Vinciguerra, Claudia, Bevilacqua, Liliana, Brighina, Filippo, Rini, Nicasio, Puorro, Giorgia, Marsili, Angela, Garibaldi, Matteo, Fionda, Laura, Saccà, Francesco
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2024 Springer Nature B.V
Subjects:	Activities of Daily Living Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - pharmacology Complement Inactivating Agents - administration & dosage Complement Inactivating Agents - pharmacology Fc receptors Female Follow-Up Studies Humans Male Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Myasthenia gravis Myasthenia Gravis - drug therapy Neonates Neurology Neuromuscular junctions Neuroradiology Neurosciences Original Communication Patients Prednisone Receptors, Cholinergic - immunology Steroids Treatment Outcome Vaccination Innovative QMG Observational MG-ADL Seronegative Real-world evidence
ISSN:	0340-5354, 1432-1459, 1432-1459
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Introduction Eculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat generalized myasthenia gravis (gMG) patients. The objective of this study is to describe the clinical response to both treatments in a real-life setting. Methods We collected baseline and follow-up clinical data using the Myasthenia Gravis-Activities of Daily Living (MG-ADL), and Quantitative Myasthenia Gravis (QMG). We included 63 patients, 32 treated with eculizumab and 31 with efgartigimod. Of the efgartigimod-treated patients, 22 were anti-acetylcholine receptor antibody-positive (AChR-Ab +) and 9 were AChR-Ab- (3 MuSK-Ab + and 6 seronegative). Results Both treatments showed similar efficacy relative to the MG-ADL scale reduction ( p = 0.237). Efgartigimod had a similar effect on both AChR-Ab + and AChR-Ab- ( p = 0.280). Eculizumab was superior to efgartigimod relative to the QMG score reduction for the entire dataset ( p = 0.003) and was more likely to achieve a clinical response at the QMG compared to efgartigimod (OR 1.373; p = 0.016). Steroid-sparing effect was higher for eculizumab than efgartigimod ( – 16.7 vs – 5.2 mg of the baseline daily dose at follow-up; p = 0.001). Mean speed of prednisone reduction was – 13.1 mg of the daily dose for each month of follow-up for eculizumab-treated patients and – 3.2 for efgartigimod ( p = 0.001). We found three serious events, all not related to treatment in the investigator’s opinion. One eculizumab-treated patient experienced a severe pneumonia and died despite treatment. Conclusions Our study provides evidence that eculizumab and efgartigimod can be used in clinical practice to reduce disability in gMG patients. Eculizumab-treated patients had a higher QMG response and steroid sparing effect. Efgartigimod may offer a more flexible schedule due to its cyclical use, no need for vaccination, and efficacy in AChR-Ab- patients.
AbstractList	Eculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat generalized myasthenia gravis (gMG) patients. The objective of this study is to describe the clinical response to both treatments in a real-life setting.INTRODUCTIONEculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat generalized myasthenia gravis (gMG) patients. The objective of this study is to describe the clinical response to both treatments in a real-life setting.We collected baseline and follow-up clinical data using the Myasthenia Gravis-Activities of Daily Living (MG-ADL), and Quantitative Myasthenia Gravis (QMG). We included 63 patients, 32 treated with eculizumab and 31 with efgartigimod. Of the efgartigimod-treated patients, 22 were anti-acetylcholine receptor antibody-positive (AChR-Ab +) and 9 were AChR-Ab- (3 MuSK-Ab + and 6 seronegative).METHODSWe collected baseline and follow-up clinical data using the Myasthenia Gravis-Activities of Daily Living (MG-ADL), and Quantitative Myasthenia Gravis (QMG). We included 63 patients, 32 treated with eculizumab and 31 with efgartigimod. Of the efgartigimod-treated patients, 22 were anti-acetylcholine receptor antibody-positive (AChR-Ab +) and 9 were AChR-Ab- (3 MuSK-Ab + and 6 seronegative).Both treatments showed similar efficacy relative to the MG-ADL scale reduction (p = 0.237). Efgartigimod had a similar effect on both AChR-Ab + and AChR-Ab- (p = 0.280). Eculizumab was superior to efgartigimod relative to the QMG score reduction for the entire dataset (p = 0.003) and was more likely to achieve a clinical response at the QMG compared to efgartigimod (OR 1.373; p = 0.016). Steroid-sparing effect was higher for eculizumab than efgartigimod ( - 16.7 vs - 5.2 mg of the baseline daily dose at follow-up; p = 0.001). Mean speed of prednisone reduction was - 13.1 mg of the daily dose for each month of follow-up for eculizumab-treated patients and - 3.2 for efgartigimod (p = 0.001). We found three serious events, all not related to treatment in the investigator's opinion. One eculizumab-treated patient experienced a severe pneumonia and died despite treatment.RESULTSBoth treatments showed similar efficacy relative to the MG-ADL scale reduction (p = 0.237). Efgartigimod had a similar effect on both AChR-Ab + and AChR-Ab- (p = 0.280). Eculizumab was superior to efgartigimod relative to the QMG score reduction for the entire dataset (p = 0.003) and was more likely to achieve a clinical response at the QMG compared to efgartigimod (OR 1.373; p = 0.016). Steroid-sparing effect was higher for eculizumab than efgartigimod ( - 16.7 vs - 5.2 mg of the baseline daily dose at follow-up; p = 0.001). Mean speed of prednisone reduction was - 13.1 mg of the daily dose for each month of follow-up for eculizumab-treated patients and - 3.2 for efgartigimod (p = 0.001). We found three serious events, all not related to treatment in the investigator's opinion. One eculizumab-treated patient experienced a severe pneumonia and died despite treatment.Our study provides evidence that eculizumab and efgartigimod can be used in clinical practice to reduce disability in gMG patients. Eculizumab-treated patients had a higher QMG response and steroid sparing effect. Efgartigimod may offer a more flexible schedule due to its cyclical use, no need for vaccination, and efficacy in AChR-Ab- patients.CONCLUSIONSOur study provides evidence that eculizumab and efgartigimod can be used in clinical practice to reduce disability in gMG patients. Eculizumab-treated patients had a higher QMG response and steroid sparing effect. Efgartigimod may offer a more flexible schedule due to its cyclical use, no need for vaccination, and efficacy in AChR-Ab- patients. Introduction Eculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat generalized myasthenia gravis (gMG) patients. The objective of this study is to describe the clinical response to both treatments in a real-life setting. Methods We collected baseline and follow-up clinical data using the Myasthenia Gravis-Activities of Daily Living (MG-ADL), and Quantitative Myasthenia Gravis (QMG). We included 63 patients, 32 treated with eculizumab and 31 with efgartigimod. Of the efgartigimod-treated patients, 22 were anti-acetylcholine receptor antibody-positive (AChR-Ab +) and 9 were AChR-Ab- (3 MuSK-Ab + and 6 seronegative). Results Both treatments showed similar efficacy relative to the MG-ADL scale reduction ( p = 0.237). Efgartigimod had a similar effect on both AChR-Ab + and AChR-Ab- ( p = 0.280). Eculizumab was superior to efgartigimod relative to the QMG score reduction for the entire dataset ( p = 0.003) and was more likely to achieve a clinical response at the QMG compared to efgartigimod (OR 1.373; p = 0.016). Steroid-sparing effect was higher for eculizumab than efgartigimod ( – 16.7 vs – 5.2 mg of the baseline daily dose at follow-up; p = 0.001). Mean speed of prednisone reduction was – 13.1 mg of the daily dose for each month of follow-up for eculizumab-treated patients and – 3.2 for efgartigimod ( p = 0.001). We found three serious events, all not related to treatment in the investigator’s opinion. One eculizumab-treated patient experienced a severe pneumonia and died despite treatment. Conclusions Our study provides evidence that eculizumab and efgartigimod can be used in clinical practice to reduce disability in gMG patients. Eculizumab-treated patients had a higher QMG response and steroid sparing effect. Efgartigimod may offer a more flexible schedule due to its cyclical use, no need for vaccination, and efficacy in AChR-Ab- patients. Eculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat generalized myasthenia gravis (gMG) patients. The objective of this study is to describe the clinical response to both treatments in a real-life setting. We collected baseline and follow-up clinical data using the Myasthenia Gravis-Activities of Daily Living (MG-ADL), and Quantitative Myasthenia Gravis (QMG). We included 63 patients, 32 treated with eculizumab and 31 with efgartigimod. Of the efgartigimod-treated patients, 22 were anti-acetylcholine receptor antibody-positive (AChR-Ab +) and 9 were AChR-Ab- (3 MuSK-Ab + and 6 seronegative). Both treatments showed similar efficacy relative to the MG-ADL scale reduction (p = 0.237). Efgartigimod had a similar effect on both AChR-Ab + and AChR-Ab- (p = 0.280). Eculizumab was superior to efgartigimod relative to the QMG score reduction for the entire dataset (p = 0.003) and was more likely to achieve a clinical response at the QMG compared to efgartigimod (OR 1.373; p = 0.016). Steroid-sparing effect was higher for eculizumab than efgartigimod ( - 16.7 vs - 5.2 mg of the baseline daily dose at follow-up; p = 0.001). Mean speed of prednisone reduction was - 13.1 mg of the daily dose for each month of follow-up for eculizumab-treated patients and - 3.2 for efgartigimod (p = 0.001). We found three serious events, all not related to treatment in the investigator's opinion. One eculizumab-treated patient experienced a severe pneumonia and died despite treatment. Our study provides evidence that eculizumab and efgartigimod can be used in clinical practice to reduce disability in gMG patients. Eculizumab-treated patients had a higher QMG response and steroid sparing effect. Efgartigimod may offer a more flexible schedule due to its cyclical use, no need for vaccination, and efficacy in AChR-Ab- patients. IntroductionEculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat generalized myasthenia gravis (gMG) patients. The objective of this study is to describe the clinical response to both treatments in a real-life setting.MethodsWe collected baseline and follow-up clinical data using the Myasthenia Gravis-Activities of Daily Living (MG-ADL), and Quantitative Myasthenia Gravis (QMG). We included 63 patients, 32 treated with eculizumab and 31 with efgartigimod. Of the efgartigimod-treated patients, 22 were anti-acetylcholine receptor antibody-positive (AChR-Ab +) and 9 were AChR-Ab- (3 MuSK-Ab + and 6 seronegative).ResultsBoth treatments showed similar efficacy relative to the MG-ADL scale reduction (p = 0.237). Efgartigimod had a similar effect on both AChR-Ab + and AChR-Ab- (p = 0.280). Eculizumab was superior to efgartigimod relative to the QMG score reduction for the entire dataset (p = 0.003) and was more likely to achieve a clinical response at the QMG compared to efgartigimod (OR 1.373; p = 0.016). Steroid-sparing effect was higher for eculizumab than efgartigimod ( – 16.7 vs – 5.2 mg of the baseline daily dose at follow-up; p = 0.001). Mean speed of prednisone reduction was – 13.1 mg of the daily dose for each month of follow-up for eculizumab-treated patients and – 3.2 for efgartigimod (p = 0.001). We found three serious events, all not related to treatment in the investigator’s opinion. One eculizumab-treated patient experienced a severe pneumonia and died despite treatment.ConclusionsOur study provides evidence that eculizumab and efgartigimod can be used in clinical practice to reduce disability in gMG patients. Eculizumab-treated patients had a higher QMG response and steroid sparing effect. Efgartigimod may offer a more flexible schedule due to its cyclical use, no need for vaccination, and efficacy in AChR-Ab- patients.
Author	Garibaldi, Matteo Saccà, Francesco Marsili, Angela Puorro, Giorgia Di Stefano, Vincenzo Brighina, Filippo Rini, Nicasio Sarnataro, Alessio Cuomo, Nunzia Vinciguerra, Claudia Bevilacqua, Liliana Pane, Chiara Fionda, Laura
Author_xml	– sequence: 1 givenname: Chiara surname: Pane fullname: Pane, Chiara organization: Neuroscience, Reproductive and Odontostomatological Sciences (NSRO) Department, Federico II University – sequence: 2 givenname: Vincenzo surname: Di Stefano fullname: Di Stefano, Vincenzo organization: Biomedicine, Neuroscience and Advanced Diagnostic (BIND) Department, University of Palermo – sequence: 3 givenname: Nunzia surname: Cuomo fullname: Cuomo, Nunzia organization: Neuroscience, Reproductive and Odontostomatological Sciences (NSRO) Department, Federico II University – sequence: 4 givenname: Alessio surname: Sarnataro fullname: Sarnataro, Alessio organization: Neuroscience, Reproductive and Odontostomatological Sciences (NSRO) Department, Federico II University – sequence: 5 givenname: Claudia surname: Vinciguerra fullname: Vinciguerra, Claudia organization: Neurology Unit, Medicine, Surgery and Dentistry Department, University of Salerno – sequence: 6 givenname: Liliana surname: Bevilacqua fullname: Bevilacqua, Liliana organization: Neurology Unit, Medicine, Surgery and Dentistry Department, University of Salerno – sequence: 7 givenname: Filippo surname: Brighina fullname: Brighina, Filippo organization: Biomedicine, Neuroscience and Advanced Diagnostic (BIND) Department, University of Palermo – sequence: 8 givenname: Nicasio surname: Rini fullname: Rini, Nicasio organization: Biomedicine, Neuroscience and Advanced Diagnostic (BIND) Department, University of Palermo – sequence: 9 givenname: Giorgia surname: Puorro fullname: Puorro, Giorgia organization: Neuroscience, Reproductive and Odontostomatological Sciences (NSRO) Department, Federico II University – sequence: 10 givenname: Angela surname: Marsili fullname: Marsili, Angela organization: Neuroscience, Reproductive and Odontostomatological Sciences (NSRO) Department, Federico II University – sequence: 11 givenname: Matteo surname: Garibaldi fullname: Garibaldi, Matteo organization: Neuromuscular and Rare Disease Centre, Neurology Unit, Sant’Andrea Hospital, Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome – sequence: 12 givenname: Laura surname: Fionda fullname: Fionda, Laura organization: Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome – sequence: 13 givenname: Francesco orcidid: 0000-0002-1323-6317 surname: Saccà fullname: Saccà, Francesco email: francesco.sacca@unina.it organization: Neuroscience, Reproductive and Odontostomatological Sciences (NSRO) Department, Federico II University, Genesis Department, Università Degli Studi Di Napoli “Federico II University”
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/39080054$$D View this record in MEDLINE/PubMed
BookMark	eNp9kcFu1TAQRS1URF8LP8ACWWLTjWEc27G9rCooSJXYwNpynEnqKnEedgItX4_LKyB10ZUXPmdmdO8JOUpLQkJec3jHAfT7AiC5YtBIxhtlDNPPyI5L0TAulT0iOxASmBJKHpOTUm4AwNSPF-RYWDAASu6IP6cZ_cSmOCDF2z3miCkg_RnXa4phm-KvbfYd9amnOIw-r3GM89LTmOiICbOvBPZ0vvNlvcYUPR2z_xEL3fu1jlrLS_J88FPBVw_vKfn28cPXi0_s6svl54vzKxYktyuTWmphQ-AqQNdaPTRBcdthO6DUFhqDrR40WtsbK2WjOtXazkAnZddbyYM4JWeHufu8fN-wrG6OJeA0-YTLVpwA0woDreQVffsIvVm2nOp1TtRkrb3fUKk3D9TWzdi7fY6zz3fub3gVaA5AyEspGYd_CAd335A7NORqQ-5PQ05XyTySQlxrVEtas4_T06o4qKXuSSPm_2c_Yf0GzKWkJw
CitedBy_id	crossref_primary_10_1177_17562864241309431 crossref_primary_10_1007_s00415_025_13267_x crossref_primary_10_1177_17562864241311127 crossref_primary_10_1007_s00415_025_13225_7 crossref_primary_10_1177_17562864251332037 crossref_primary_10_1007_s10072_025_08128_4 crossref_primary_10_1016_j_bbih_2025_101091 crossref_primary_10_1007_s00415_025_13113_0 crossref_primary_10_1007_s40801_024_00457_8 crossref_primary_10_1016_j_clineuro_2025_109011 crossref_primary_10_1080_21505594_2025_2545570 crossref_primary_10_1080_03007995_2025_2497906 crossref_primary_10_1177_17562864251326778 crossref_primary_10_1007_s10072_024_07861_6 crossref_primary_10_1007_s40259_024_00701_1 crossref_primary_10_1177_17562864251319656 crossref_primary_10_2147_CLEP_S514738 crossref_primary_10_3389_fneur_2024_1474508 crossref_primary_10_1007_s40265_024_02101_9 crossref_primary_10_1080_14728214_2025_2458061 crossref_primary_10_3390_brainsci15040350 crossref_primary_10_1007_s00415_025_13127_8 crossref_primary_10_1007_s10072_025_08096_9
Cites_doi	10.1002/mus.20950 10.1016/S1474-4422(21)00159-9 10.1177/1941875210382918 10.3233/JND-200584 10.1007/s10072-023-06900-y 10.1111/ene.16189 10.1101/2024.01.31.24302082 10.1212/WNL.52.7.1487 10.3389/fneur.2023.1284444 10.1016/S1474-4422(17)30369-1 10.1002/mus.28003 10.1212/01.WNL.0000163988.28892.79 10.1056/NEJMra1602678 10.1212/WNL.98.18_supplement.1391 10.1212/WNL.96.15_supplement.1917 10.1016/S1474-4422(15)00145-3 10.1111/ene.16180 10.1111/ene.15872 10.1002/mus.27974 10.1111/ene.16280 10.1212/CPJ.0000000000200276
ContentType	Journal Article
Copyright	The Author(s) 2024 corrected publication 2025 2024. The Author(s). Copyright Springer Nature B.V. Sep 2024
Copyright_xml	– notice: The Author(s) 2024 corrected publication 2025 – notice: 2024. The Author(s). – notice: Copyright Springer Nature B.V. Sep 2024
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TK 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8
DOI	10.1007/s00415-024-12588-7
DatabaseName	Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE ProQuest One Academic Middle East (New)
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1432-1459
EndPage	6219
ExternalDocumentID	39080054 10_1007_s00415_024_12588_7
Genre	Journal Article
GrantInformation_xml	– fundername: Università degli Studi di Napoli Federico II
GroupedDBID	--- -Y2 .55 .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 2.D 203 28- 29L 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3SX 4.4 406 408 409 40D 40E 53G 5QI 5RE 5VS 67Z 6NX 78A 7X7 88E 8AO 8FI 8FJ 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAPKM AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBRH ABBXA ABDBE ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHIR ADHKG ADIMF ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFDZB AFEXP AFFNX AFJLC AFKRA AFLOW AFOHR AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGQPQ AGRTI AGVAE AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHPBZ AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ AXYYD AYFIA AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI C6C CAG CCPQU COF CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 EPAXT ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PHGZT PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK6 WK8 X7M YLTOR Z45 ZGI ZMTXR ZOVNA ZXP ~EX ~KM AAYXX ABFSG ABRTQ ACSTC AEZWR AFFHD AFHIU AHWEU AIXLP ATHPR CITATION PHGZM PJZUB PPXIY CGR CUY CVF ECM EIF NPM 3V. 7TK 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO
ID	FETCH-LOGICAL-c419t-474739cc15c0b697f2c519be6fe479028e67f7e99d894425b569b80b44bd941c3
IEDL.DBID	RSV
ISICitedReferencesCount	30
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001280378200003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0340-5354 1432-1459
IngestDate	Fri Sep 05 08:22:37 EDT 2025 Wed Nov 05 06:29:45 EST 2025 Fri May 02 01:40:14 EDT 2025 Sat Nov 29 07:57:40 EST 2025 Tue Nov 18 22:18:34 EST 2025 Wed Apr 30 01:17:49 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	9
Keywords	Innovative QMG Observational MG-ADL Seronegative Real-world evidence
Language	English
License	2024. The Author(s).
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c419t-474739cc15c0b697f2c519be6fe479028e67f7e99d894425b569b80b44bd941c3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0002-1323-6317
OpenAccessLink	https://link.springer.com/10.1007/s00415-024-12588-7
PMID	39080054
PQID	3100999442
PQPubID	47196
PageCount	11
ParticipantIDs	proquest_miscellaneous_3086380641 proquest_journals_3100999442 pubmed_primary_39080054 crossref_primary_10_1007_s00415_024_12588_7 crossref_citationtrail_10_1007_s00415_024_12588_7 springer_journals_10_1007_s00415_024_12588_7
PublicationCentury	2000
PublicationDate	20240900 2024-09-00 2024-Sep 20240901
PublicationDateYYYYMMDD	2024-09-01
PublicationDate_xml	– month: 9 year: 2024 text: 20240900
PublicationDecade	2020
PublicationPlace	Berlin/Heidelberg
PublicationPlace_xml	– name: Berlin/Heidelberg – name: Germany – name: Heidelberg
PublicationTitle	Journal of neurology
PublicationTitleAbbrev	J Neurol
PublicationTitleAlternate	J Neurol
PublicationYear	2024
Publisher	Springer Berlin Heidelberg Springer Nature B.V
Publisher_xml	– name: Springer Berlin Heidelberg – name: Springer Nature B.V
References	J Suh (12588_CR3) 2013; 86 C Vinciguerra (12588_CR22) 2023; 44 F Saccà (12588_CR4) 2023; 20 JF Howard Jr (12588_CR18) 2024; 14 RS Bedlack (12588_CR17) 2005; 64 N Katyal (12588_CR21) 2023; 68 JF Howard Jr (12588_CR5) 2017; 16 JF Howard Jr (12588_CR6) 2021; 20 D Grob (12588_CR8) 2008; 37 R Frangiamore (12588_CR13) 2024; 31 12588_CR16 NE Gilhus (12588_CR1) 2016; 375 A Meisel (12588_CR19) 2024 M Singer (12588_CR20) 2024; 69 S Suzuki (12588_CR15) 2024; 14 NE Gilhus (12588_CR2) 2015; 14 H Murai (12588_CR12) 2022 LC Wendell (12588_CR7) 2011; 1 S Muppidi (12588_CR11) 2021 F Saccà (12588_CR9) 2023; 30 JM Dionísio (12588_CR14) 2024 N Katyal (12588_CR10) 2021; 8 40299078 - J Neurol. 2025 Apr 29;272(5):366. doi: 10.1007/s00415-025-13061-9.
References_xml	– volume: 37 start-page: 141 year: 2008 ident: 12588_CR8 publication-title: Muscle Nerve doi: 10.1002/mus.20950 – volume: 20 start-page: 526 year: 2021 ident: 12588_CR6 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(21)00159-9 – volume: 1 start-page: 16 year: 2011 ident: 12588_CR7 publication-title: Neurohospitalist doi: 10.1177/1941875210382918 – volume: 8 start-page: 287 year: 2021 ident: 12588_CR10 publication-title: J Neuromuscul Dis doi: 10.3233/JND-200584 – volume: 44 start-page: 3707 year: 2023 ident: 12588_CR22 publication-title: Neurol Sci doi: 10.1007/s10072-023-06900-y – volume: 31 issue: 4 year: 2024 ident: 12588_CR13 publication-title: Eur J Neurol doi: 10.1111/ene.16189 – year: 2024 ident: 12588_CR14 publication-title: Medrxiv doi: 10.1101/2024.01.31.24302082 – ident: 12588_CR16 doi: 10.1212/WNL.52.7.1487 – volume: 86 start-page: 255 year: 2013 ident: 12588_CR3 publication-title: Yale J Biol Med – volume: 14 start-page: 1284444 year: 2024 ident: 12588_CR18 publication-title: Front Neurol doi: 10.3389/fneur.2023.1284444 – volume: 16 start-page: 976 year: 2017 ident: 12588_CR5 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(17)30369-1 – volume: 69 start-page: 87 year: 2024 ident: 12588_CR20 publication-title: Muscle Nerve doi: 10.1002/mus.28003 – volume: 64 start-page: 1968 year: 2005 ident: 12588_CR17 publication-title: Neurology doi: 10.1212/01.WNL.0000163988.28892.79 – volume: 375 start-page: 2570 year: 2016 ident: 12588_CR1 publication-title: N Engl J Med doi: 10.1056/NEJMra1602678 – year: 2022 ident: 12588_CR12 publication-title: Neurology doi: 10.1212/WNL.98.18_supplement.1391 – year: 2021 ident: 12588_CR11 publication-title: Neurology doi: 10.1212/WNL.96.15_supplement.1917 – volume: 14 start-page: 1023 year: 2015 ident: 12588_CR2 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(15)00145-3 – volume: 20 year: 2023 ident: 12588_CR4 publication-title: Eur J Neurol doi: 10.1111/ene.16180 – volume: 30 start-page: 3854 year: 2023 ident: 12588_CR9 publication-title: Eur J Neurol doi: 10.1111/ene.15872 – volume: 68 start-page: 762 year: 2023 ident: 12588_CR21 publication-title: Muscle Nerve doi: 10.1002/mus.27974 – year: 2024 ident: 12588_CR19 publication-title: Eur J Neurol doi: 10.1111/ene.16280 – volume: 14 year: 2024 ident: 12588_CR15 publication-title: Neurol Clin Pract doi: 10.1212/CPJ.0000000000200276 – reference: 40299078 - J Neurol. 2025 Apr 29;272(5):366. doi: 10.1007/s00415-025-13061-9.
SSID	ssj0008459
Score	2.5566373
Snippet	Introduction Eculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat... Eculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat generalized myasthenia... IntroductionEculizumab, a complement active antibody, and efgartigimod, an Fc fragment that blocks neonatal Fc receptor, are both approved to treat generalized...
SourceID	proquest pubmed crossref springer
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	6209
SubjectTerms	Activities of Daily Living Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - pharmacology Complement Inactivating Agents - administration & dosage Complement Inactivating Agents - pharmacology Fc receptors Female Follow-Up Studies Humans Male Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Myasthenia gravis Myasthenia Gravis - drug therapy Neonates Neurology Neuromuscular junctions Neuroradiology Neurosciences Original Communication Patients Prednisone Receptors, Cholinergic - immunology Steroids Treatment Outcome Vaccination
SummonAdditionalLinks	– databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwEB3BFqFeKF9tQwtyJW5gkWwmTnxCpWrFAVZVBai3yHYmq0jbbNvsItFfjyfrTYUqeuk5TuJknsfPM_YbgPeqrk2cUyKdn-wl1lZL7fy4SkysKhebhHo5hl_f8smkOD_XpyHg1oVtlWuf2Dvqau44Rv6JA9GezCCOP19eSa4axdnVUELjMWywUhmOYOPL8eT0bPDFBfbl0uIUY5mlGYZjM_3hOZaa4tPJrNuXebzk_05Nd_jmnVxpPwWdbD2088_hWSCf4nCFlhfwiNqX8PR7SK-_AnMoPIecyVlTk6BBBFlwsFZwFd3mZnlhrDBtJaieMuqm3taVaFoxXelXNzdUiYs_pmNVhcYILm_UdCLIt3av4efJ8Y-jrzLUYJAOE72Q6JcbqXYuyVxslc7rsfOcz5KqCXNWfiGV1zlpXRX8eZnNlLZFbBFtpTFx6TaM2nlLuyBsXCHr0ZP3a5iS88QsRev5iFGkFLoIkvXvL10QKOc6GbNykFbuTVZ6k5W9yco8gg_DPZcreY57W--vzVOGodqVt7aJ4GC47AcZZ05MS_Olb-MXfmnh2VsSwc4KDcPrUs2kO8MIPq7hcfvw__flzf192YPNMUOz3822D6PF9ZLewhP3e9F01-8CzP8C-W0A3A priority: 102 providerName: ProQuest
Title	A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients
URI	https://link.springer.com/article/10.1007/s00415-024-12588-7 https://www.ncbi.nlm.nih.gov/pubmed/39080054 https://www.proquest.com/docview/3100999442 https://www.proquest.com/docview/3086380641
Volume	271
WOSCitedRecordID	wos001280378200003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1432-1459 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0008459 issn: 0340-5354 databaseCode: 7X7 dateStart: 20240101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1432-1459 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0008459 issn: 0340-5354 databaseCode: BENPR dateStart: 20240101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1432-1459 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0008459 issn: 0340-5354 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB7xUsWl0PJKgZUr9QaREuLY8ZFWIA50hWiL9hbZzmQVaQmI7CLBr2fsTVJVPCR6ySWOY83D8yXj-QbgmyhLHUmMQ0vBPuSlUaGy5FexjkRhIx2jp2O4OpfDYTYaqYu2KKzpTrt3KUm_U_fFbo4aylUTO569lPQrF2GZwl3m3PHy11W__2bct0iLEh6FaZLytlTm5Tn-DUfPMOaz_KgPO6dr_7fgdfjYwkx2PLeLT7CA9Wf48LNNpG-APmaEFifhpCqRYU93zNxvWeb65VaPs2ttmK4LhuXY2deYtFqwqmbjOVN19YgFu37QjeNPqDRzjYyqhrVErc0m_Dk9-f3jLGy7LYSWx2oacvqwSJS1cWojI5QsjyyhO4OiRC4dxwsKWUpUqsgUJ083qVAmiwznplA8tskWLNU3Ne4AM1HBHfM80g7GE7QEwRJuCHlogUJwG0DcCT23LRW564gxyXsSZS-7nGSXe9nlMoCD_pnbORHHm6P3Ol3mrVM2uctlEB6mxQfwtb9N7uRyJLrGmxmNoU-8JCOcFgewPbeB_nWJcvA65QEcdgr_O_nra_nyvuG7sHrkbMafY9uDpendDPdhxd5Pq-ZuAItyJP01G8Dy95PhxeXAm_8T06D47g
linkProvider	Springer Nature
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgoBLeZfQAkaCE1jk4cTxoUIVULXqdsWhoL0F23FWkbbZttkFtT-K39iZvCpU0VsPnOPYTvzN-LM9_gbgbVIU2pcu4BYney4Ko7iyaFeB9pPc-jpwjRzDj5Ecj9PJRH1bgT_9XRgKq-x9YuOo87mlPfKPtBGNZEaI8NPxCaesUXS62qfQaGGx785-45Kt3tr7guP7Lgx3vh5-3uVdVgFuRaAWXCCBjpS1QWx9kyhZhBZZjHFJ4YQkLROXyEI6pfKUWotNnCiT-kYIkysR2AjrvQW30Y9LCiGTk2GB56eiSc7mR8LncRSL7pJOc1WPhK3oLjSpBMaITvn3RHiF3V45mW0mvJ0H_9uveghrHbVm260tPIIVVz2Guwdd8MAT0NsMGfKMz8rCMTdIPDPaimaUI7g8Xx5pw3SVM1dMyaamiOSclRWbturc5bnL2dGZrkkzotSMkjeVNevEaeun8P1GPvAZrFbzyj0HZvxckNq-Q68tImeRdkbCINvSiUsSYT0I-uHObCe_TllAZtkgHN1AJEOIZA1EMunB--Gd41Z85NrSmz0css4R1dklFjx4MzxGF0LnQrpy8yWWwWVtlCI3DTxYb9E3NBcpWlLEwoMPPRwvK_93X15c35fXcG_38GCUjfbG-xtwPySzaOL2NmF1cbp0L-GO_bUo69NXjYEx-HnTML0Ax-habw
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VLaq48H4EChgJThA1D8eJDwgV2hVVy2qFAPUWbMdeRdpmS7MLan8av46ZvCpU0VsPnOPYTvzN-LM9_gbgpXBOBakNfYOTvc-dlr40aFehCkRhAhXaRo7h20E6mWSHh3K6Br_7uzAUVtn7xMZRFwtDe-RbtBGNZIbzaMt1YRHTnfG74x8-ZZCik9Y-nUYLkX17-guXb_XbvR0c61dRNN798uGj32UY8A0P5dLnSKZjaUyYmEALmbrIIKPRVjjLU9I1sSJ1qZWyyKjlRCdC6izQnOtC8tDEWO81WMc6omQE6-93J9PPwzyQ8SZVWxDzwE_ihHdXdpqLeyRzRTejSTMwQaymf0-LF7juhXPaZvob3_qff9xtuNmRbrbdWskdWLPVXdj41IUV3AO1zZA7z_156Syzg_gzo01qRtmDy7PVkdJMVQWzbkbWNkOMF6ys2KzV7S7PbMGOTlVNahKlYpTWqaxZJ1tb34evV_KBD2BULSr7CJgOCk46_Bb9OY-tQUIac408TAkrBDcehP3Q56YTZqf8IPN8kJRu4JIjXPIGLnnqwevhneNWluTS0ps9NPLORdX5OS48eDE8RudCJ0aqsosVlsEFb5whaw09eNgicWgulrTYSLgHb3ponlf-7748vrwvz2ED0Zkf7E32n8CNiCykCejbhNHyZGWfwnXzc1nWJ886a2Pw_apx-gdTJWSP
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+real-life+experience+with+eculizumab+and+efgartigimod+in+generalized+myasthenia+gravis+patients&rft.jtitle=Journal+of+neurology&rft.au=Pane%2C+Chiara&rft.au=Di+Stefano%2C+Vincenzo&rft.au=Cuomo%2C+Nunzia&rft.au=Sarnataro%2C+Alessio&rft.date=2024-09-01&rft.pub=Springer+Berlin+Heidelberg&rft.issn=0340-5354&rft.eissn=1432-1459&rft.volume=271&rft.issue=9&rft.spage=6209&rft.epage=6219&rft_id=info:doi/10.1007%2Fs00415-024-12588-7&rft.externalDocID=10_1007_s00415_024_12588_7
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0340-5354&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0340-5354&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0340-5354&client=summon